From: Impaired type I interferon regulation in the blood transcriptome of recurrent asthma exacerbations
 | Single AETRI | Non-infectious AEs | Multiple AETRIs |
---|---|---|---|
 | (N = 41) | (N = 38) | (N = 11) |
Exacerbation samples (n) | 41 | 38 | 27 |
Baseline samples (n) | 147 | 124 | 32 |
Female Gender | 28 (68%) | 22 (58%) | 9 (82%) |
White Race | 36 (88%) | 33 (87%) | 10 (91%) |
BMI, kg/m2 | 27.7 [24.5–31.3] | 27.8 [24.7–32.0] | 34.2 [27.9–38.7] |
GERD | 8 (20%) | 13 (34%) | 6 (55%) |
Atopy Status | |||
 Atopic | 27 (66%) | 25 (66%) | 8 (73%) |
 Non-Atopic | 9 (22%) | 8 (21%) | 1 (9%) |
 Unknown | 5 (12%) | 5 (13%) | 2 (18%) |
Asthma Severity at the time of Exacerbation | |||
 Mild Persistent | 5 (12%) | 2 (5%) | 0 (0%) |
 Moderate Persistent | 20 (49%) | 16 (42%) | 4 (36%) |
 Severe Persistent | 16 (39%) | 20 (53%) | 7 (64%) |
FEV1 predicted (%) | 88 [65–98] | 78 [62–87] | 62 [45–95] |
IgE level, IU/ml | 107 [46–224] | 117 [53–198] | 64 [47–65] |
Inhaled CS use | 13 (32%) | 19 (50%) | 10 (91%) |
Systemic CS use | 15 (37%) | 12 (32%) | 4 (36%) |
Leukotriene receptor antagonist use | 15 (37%) | 12 (32%) | 4 (36%) |
Maximum steroid exposure during an exacerbation | |||
 Systemic | 13 (32%) | 19 (50%) | 10 (91%) |
 Inhaled | 27 (66%) | 19 (50%) | 1 (9%) |
 Other | 1 (2%) | 0 (0%) | 0 (0%) |
Bactin-GAPDH 5′ 3′ ratio exacerbation | 0.86 [0.77–0.96] | 0.84 [0.78–0.95] | 0.86 [0.69–0.93] |
Bactin-GAPDH 5′ 3′ ratio baseline | 0.85 [0.70–0.93] | 0.84 [0.73–0.92] | 0.85 [0.73–0.92] |
Ratio of M:L whole blood exacerbation | 0.19 [0.15–0.32] | 0.26 [0.15–0.31] | 0.24 [0.20–0.33] |
Ratio of M:L whole blood baseline | 0.17 [0.13–0.22] | 0.20 [0.15–0.26] | 0.23 [0.21–0.26] |